Keeping Track: FDA Approval Activity Heats Up With Ocaliva, Zinbryta And More
Executive Summary
The latest drug development news and highlights from our FDA Performance Tracker.
You may also be interested in...
Intercept’s Ocaliva: ‘Dangling’ PBC Indication At Risk As Near-Term NASH Approval Looks Unlikely
Accelerated approval for primary biliary cholangitis in 2016 came with three postmarketing requirements, but studies were terminated early; firm working toward sNDA submission in 2023 for regular approval, but US FDA says reports already are overdue and it expects to take PBC indication back to an adcomm.
Keeping Track: Approval Of First Intranasal Naloxone Copycat Highlights Otherwise Generic Week
The latest drug development news and highlights from our US FDA Performance Tracker.
Keeping Track: Rebuff Of Iclaprim Creates Early Pileup Of CRLs For Novel Drugs
The latest drug development news and highlights from our US FDA Performance Tracker.